Sandbox: HCL therapy: Difference between revisions

Revision as of 22:59, 29 October 2015

Indications to initiate medical therapy among patients with hairy cell leukemia include:

The presence of systemic symptoms such as fever, night sweats, and significant weight loss
The presence of subcostal abdominal discomfort due splenic distension
Positive history of recurrent infections.
Hemoglobin concentration lower than 12 g/dl
Platelets count lower than 100,000/mcl
Absolute neutrophil count lower than 1000/mcl

Pharmacological agents used for the treatment of hairy cell leukemia patients include:

@@ Line 14: / Line 14: @@
 :* [[Rituximab]]
 :* [[Interferon alpha]]
 :* [[Vemurafenib]]
-Patients presenting with thrombocytopenia or anemia due to bone marrow failure
-Patients presenting with refractory autoimmune hemolytic anemia or refractory autoimmune thrombocytopenia
-Evidence of symptomatic splenomegaly, with the spleen being palpated more than 6cm below the costal margin
-Evidence of symptomatic progressive lymph nodes swelling, with a size greater than 10 cm in diameter
-Evidence of a rapidly progressive lymphocytosis, which might be observed as:
-An increase of greater than 50% over a 2-month period
-A lymphocyte doubling period shorter than six months